Genomic Vision Extends its Patent Portfolio With the Genomic Morse Code

Informations

• Publié par: genomic-vision
• Nombre de lectures: 13
• Langue: English

Extrait

Genomic Vision Extends its Patent Portfolio

With the Genomic Morse Code

PR Newswire

PARIS, July 3, 2012

PARIS

,

July 3, 2012

/PRNewswire/ --

Genomic Vision, a leading biotechnology company specializing in developing

genetic diagnostic tests using DNA molecular combing, is announcing the

extension of its intellectual property portfolio, with the granting in several

countries of a patent on an innovative method of structural and visual analysis

of the genome, called Genomic Morse Code (GMC).

"

This new patent is in line with a solid portfolio of patents covering molecular

combing, for which Genomic Vision holds the exclusive world license. With

the GMC patent, the first of its own patents, Genomic Vision is strengthening its

competitive edge and demonstrating its innovative force,"

says Aaron

Bensimon, CEO of Genomic Vision.

The molecular combing technology allows direct microscopic visualization of

large genomic regions using fluorescent markers. They form patterns specific

to genomic locations using a limited number of colors, a little like traditional

Morse Code, hence the name Genomic Morse Code.

Example of the gene for the genetic predisposition to cancer BRCA1. Image

acquisition and analysis remain sufficiently simple thanks to the limited number

of colors. Since pattern recognition is based on the size, spacing and color of

several markers, the combinations are infinite, allowing for the coverage of any

number of genes. Rearrangements are readily identified as modifications in the

expected pattern. Photo credit: Genomic Vision©.

High-resolution technology on single DNA molecules

Genomic Morse Code is the key to diagnostics applications that make use of

this high resolution, single DNA molecule technology.

"Genomic Vision developed the GMC strategy in its effort to

develop practicable diagnostics tests with wide coverage of the genome,"

underlines Dr. Pierre Walrafen, project manager at Genomic Vision and co-

inventor of the Genomic Morse Code.

"The modularity and evolutivity of the GMC will allow the constant adaptation of

diagnostics tests to novel discoveries in the field of large rearrangements,

which is barely beginning to reveal its extent and its importance in human

health,"

he adds.

Eight patent families

The patent portfolio held by Genomic Vision in sole or joint ownership is

continuously growing, with eight new patent families so far, covering technical

developments as well as biomarkers and specific diagnostic tests involving

large genome rearrangements.

"With active research in this growing field, a powerful tool which provides a

unique vision and a network of key expert collaborators, Genomic Vision is

uniquely positioned to improve on existing approaches and make new

discoveries,"

says CEO, Aaron Bensimon.

"New opportunities, e.g. in cross-

licensing, will arise from the biomarker portfolio which will be a strong support

in the growth of Genomic Vision as a global player in the field of molecular

diagnostics."

More about molecular combing

: http://www.genomicvision.com/technology-

molecular-combing.php

More information about Genomic Vision

: http://www.genomicvision.com